Back to top

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 24, 2012 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Dr. Reddy’s Laboratories (RDY - Free Report) , GlaxoSmithKline (GSK - Free Report) , AstraZeneca (AZN - Free Report) , Merck & Co. (MRK - Free Report) and Pfizer Inc. (PFE - Free Report) .

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Friday’s Analyst Blog:


Dr. Reddy’s Launches Generic Amoxil


Dr. Reddy’s Laboratories (RDY - Free Report) recently announced the launch of its generic version of GlaxoSmithKline’s (GSK - Free Report) Amoxil (amoxicillin) tablets, capsules, and oral suspension in the US following the receipt of Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA).

Dr. Reddy’s launched its generic version of Amoxil tablets (500 mg and 875 mg), capsules (250 mg and 500 mg) and oral suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) in the US on September 17, 2012.

Amoxil is marketed for the treatment of bacterial infection of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract.

According to IMS Health, US branded and generic sales of Amoxil tablets (875 mg), capsules and oral suspension were approximately $22.2 million, $67.2 million and $89.5 million, respectively, for the twelve months ended June 30, 2012.

We note Dr. Reddy’s had quite a few generic launches this year. On September 11, 2012, it launched its generic version of AstraZeneca’s (AZN - Free Report) hypertension drug Toprol XL (metoprolol succinate extended release) - tablets (25 mg, 50 mg, 100 mg and 200 mg) in the US.

Dr. Reddy’s also launched a generic version of Merck & Co.’s (MRK - Free Report) blockbuster asthma and allergy drug Singulair and Pfizer Inc.’s (PFE - Free Report) blockbuster cholesterol drug, Lipitor.

Our Recommendation

Currently, we have a Neutral recommendation on Dr. Reddy’s. The stock carries a Zacks #3 Rank (short-term Hold rating).






Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

More from Zacks Press Releases

You May Like